Furthermore, we discuss the possibility and feasibility of utilizing CLR-mediated anti-fungal immunity as a novel effective target for synergizing and optimizing the efficacy of immune-checkpoint blockade therapy in bladder cancer. Here, DCLK3 is linked to urinary bladder cancer.